SHRED (GW-0742)

00002
AU$139.00
In stock
1
Product Details

Description

SHRED (GW-0742) is an oral SARM was primarily developed to treat obesity, diabetes, lipid strain, and heart health problems. SHRED (GW-0742) is grouped in the category of SARMS, however in structure and definition, it is a PPAR modulator. It is considered a strong treatment for obesity and other related conditions. It is our strongest and best selling fat burner. SHRED (GW-0742) possesses very strong fat loss attributes and abilities but is also known for two other major strengths; Endurance, Reduction of Cholesterol.

1. The endurance benefits that can be obtained with SHRED (GW-0742) research are unmatched. There is a strong reason that it has been banned in many professional sport settings, most notably, the Olympics, NCAA and with professional cyclists. SHRED (GW-0742) can drastically improve endurance over extended periods of time but expanding the VO2 max, allowing for continuous improvements in aerobic capacity. This allows for research subjects to reach potential that would otherwise be unattainable. SHRED (GW-0742) allows one to overcome plateaus and reach peak level.

2. SHRED (GW-0742) was originally designed to treat cholesterol and this is a characteristic that should never be forgotten, yet in many circumstances, it is. Although this is an extremely strong characteristic, this is not one of the top two major strengths it is known for. This characteristic is that of fat loss. SHRED (GW-0742) is extremely desirable because it has the ability to shed fat rapidly while staying in a non-catabolic state. SHRED (GW-0742) gives one the ability to drop fat at a far higher rate than generally possibly, yet in an extremely safe fact.

Dosage

ALL REFERENCES OF USE ARE FOR RESEARCH SUBJECTS AND NOT HUMANS

Concentration: 20mg/mL

Volume: 30mL

Dosing lengths generally run 8-16 weeks at 20 mg per day, 20 mg being the most common and most effective. Each bottle has 30ml with an average dose been around 1ml (1 full dropper squirt).

Suggested Combinations

1. Endurance: We recommend stacking SHRED (GW-0742) with MAINTAIN (MK-2866). This is the ultimate endurance stack that will turn you into a race horse.

2. AUS LABS CUT STACK: The best shredding stack would be SHRED (GW-0742) with MASS (S4). This is a well known potent ‘cutting’ stack and shows results similar to traditional thermogenic and anabolics.

3. Anabolic Steroid Stack: If you run moderate doses of anabolic steroids, or you run any harsh compound like trenbolone, then SHRED (GW-0742) will aid in not only your lipids, but also with your ability to ‘catch your wind’ (a common breathing side effect seen with tren users). Therefore, SHRED (GW-0742) is a perfect stack for trenbolone, which makes many athletes lose their breath fast.

4. During PCT (post cycle therapy) or Bridge: Since SHRED (GW-0742) is not hormonal, it is in no way suppressive. Hence, you should not be scared of using it to keep fat off and improve your workouts between cycles during your bridge and PCT.

5. AUS LABS TRIPLE STACK: If you want to make serious gains, SHRED (GW-0742) stacks beautifully with MASS (S4) and MAINTAIN (MK-2866).

Ingredients/ HPLC Purity Report

SHRED: {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid, food-grade USP glycol, food-grade ethyl alcohol and essential oils.

Please email sales@auslabs.email for the latest HPLC purity report.

Storage

Cool and dark space like a cupboard or pantry.

Medical References

  • Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8.
  • Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89.
  • Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271.
  • Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884.

No statements made on this page have been evaluated by the Bundesministerium für Gesundheit (BMG) or the Therapeutic Goods Administration (TGA). These products are not intended to treat, cure or prevent any disease or illness. All products are strictly for research purposes only. Please refer to the TERMS OF USE for more information.

Save this product for later